Principal Financial Group Inc. Buys Shares of 66,550 Fulcrum Therapeutics, Inc. $FULC

Principal Financial Group Inc. purchased a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 66,550 shares of the company’s stock, valued at approximately $612,000. Principal Financial Group Inc. owned 0.12% of Fulcrum Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. AlphaQuest LLC acquired a new position in Fulcrum Therapeutics during the 3rd quarter worth about $325,000. Y Intercept Hong Kong Ltd purchased a new stake in Fulcrum Therapeutics during the third quarter worth about $104,000. Strs Ohio lifted its position in shares of Fulcrum Therapeutics by 3.7% during the third quarter. Strs Ohio now owns 77,900 shares of the company’s stock worth $717,000 after purchasing an additional 2,800 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Fulcrum Therapeutics in the third quarter valued at approximately $943,000. Finally, Simplify Asset Management Inc. grew its holdings in shares of Fulcrum Therapeutics by 13.8% in the third quarter. Simplify Asset Management Inc. now owns 83,234 shares of the company’s stock valued at $766,000 after purchasing an additional 10,080 shares in the last quarter. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Trading Up 7.2%

Shares of NASDAQ FULC opened at $11.73 on Friday. The stock has a market cap of $634.83 million, a P/E ratio of -9.94 and a beta of 3.19. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $15.74. The stock has a 50 day moving average of $10.95 and a two-hundred day moving average of $9.37.

Insider Transactions at Fulcrum Therapeutics

In other news, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the sale, the director directly owned 469,864 shares of the company’s stock, valued at approximately $5,577,285.68. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the transaction, the insider directly owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. This represents a 40.82% decrease in their position. The SEC filing for this sale provides additional information. 7.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on FULC shares. Stifel Nicolaus set a $25.00 price target on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, January 22nd. Cantor Fitzgerald boosted their price objective on Fulcrum Therapeutics from $15.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Finally, Bank of America upped their target price on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research note on Tuesday, December 9th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $19.11.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.